Ying-Hao Shen

List of Publications by Year
in descending order

31 papers	735 citations	623734 14 h-index	580821 25 g-index
36 all docs	36 docs citations	36 times ranked	1149 citing authors

#	Article	IF	Citations
1	Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction. Surgical Innovation, 2022, 29, 145-153.	0.9	0
2	Future liver volume combined with platelet count predicts liver failure after major hepatectomy. Journal of the Royal College of Surgeons of Edinburgh, 2022, , .	1.8	0
3	Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.. Journal of Clinical Oncology, 2021, 39, 346-346.	1.6	2
4	Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 13-20.	1.3	7
5	Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations. Liver Cancer, 2021, 10, 320-329.	7.7	108
6	Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Research, 2021, 9, 19.	6.8	43
7	Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	7
8	Radiological response as a predictor of pathological response to combined tyrosine kinase inhibitor (TKI) and anti-PD-1 antibodies in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2021, 39, e16144-e16144.	1.6	1
9	Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan. Annals of Translational Medicine, 2021, 9, 756-756.	1.7	8
10	CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. Carcinogenesis, 2021, 42, 1293-1303.	2.8	16
11	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. Frontiers in Immunology, 2021, 12, 705378.	4.8	17
12	Early tumor marker decrease to predict the efficacy of combination therapy with lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2021, 39, 304-304.	1.6	2
13	A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. Surgery, 2020, 167, 926-932.	1.9	7
14	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. BioMed Research International, 2020, 2020, 1-10.	1.9	12
15	Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.. Journal of Clinical Oncology, 2020, 38, e16610-e16610.	1.6	7
16	Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection.. Journal of Clinical Oncology, 2020, 38, e16690-e16690.	1.6	11
17	Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 204-204.	1.7	25
18	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics, 2019, 9, 4678-4687.	10.0	61

#	Article	IF	Citations
19	Dexamethasone for postoperative hyperbilirubinemia in patients after liver resection: An open-label, randomized controlled trial. Surgery, 2019, 165, 534-540.	1.9	7
20	NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. Journal of Hematology and Oncology, 2018, 11, 28.	17.0	41
21	Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. American Journal of Cancer Research, 2018, 8, 1040-1049.	1.4	11
22	Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. American Journal of Translational Research (discontinued), 2018, 10, 3567-3578.	0.0	5
23	Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death and Disease, 2017, 8, 3205.	6.3	34
24	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. BMC Cancer, 2017, 17, 58.	2.6	42
25	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. International Journal of Oncology, 2016, 49, 2367-2376.	3.3	39
26	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 169-178.	1.5	32
27	Generation and characterization of a tetraspanin CD151/integrin Î±6Î²1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. Oncotarget, 2016, 7, 6314-6322.	1.8	20
28	Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. BMC Cancer, 2015, 15, 831.	2.6	34
29	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6, 846-861.	1.8	84
30	Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. Tumor Biology, 2014, 35, 4007-4015.	1.8	19
31	Focal nodular hyperplasia of the liver in 86 patients. Hepatobiliary and Pancreatic Diseases International, 2007, 6, 52-7.	1.3	31